B. Langton-Webster

发表

Homologue scanning mutagenesis of heregulin reveals receptor specific binding epitopes.

M. Adler, R. Harkins, M. Foehr, 1998, Biochemical and biophysical research communications.

Development of resistance to cisplatin is associated with decreased expression of the gp185c-erbB-2 protein and alterations in growth properties and responses to therapy in an ovarian tumor cell line.

D. Salomon, J. Xuan, J. Brink, 1994, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

Differential sensitivity to non-major histocompatibility complex-restricted recombinant interleukin 2-activated lymphocyte killing of human mammary epithelial MCF-10A cells overexpressing oncogenes or protein kinase A subunits.

P. Tagliaferri, M. Caraglia, G. Tortora, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

Preclinical Dosimetry, Imaging, and Targeted Radionuclide Therapy Studies of Lu-177-Labeled Albumin-Binding, PSMA-Targeted CTT1403

C. Laymon, B. Kurland, L. Rigatti, 2019, Molecular Imaging and Biology.

177Lu-Labeled Phosphoramidate-Based PSMA Inhibitors: The Effect of an Albumin Binder on Biodistribution and Therapeutic Efficacy in Prostate Tumor-Bearing Mice

C. Anderson, C. Berkman, Joseph D Latoche, 2017, Theranostics.

INO-4995 therapeutic efficacy is enhanced with repeat dosing in cystic fibrosis knockout mice and human epithelia.

M. Drumm, P. Majerus, S. Gabriel, 2010, American journal of respiratory cell and molecular biology.

Phase I Study of CTT1057, an 18F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer

Kirsten L. Greene, M. Cooperberg, P. Carroll, 2018, The Journal of Nuclear Medicine.

First-in-Human Phase I study of CTT1057, a Novel 18F Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate Specific Membrane Antigen in Prostate Cancer

M. Cooperberg, P. Carroll, J. Kurhanewicz, 2018 .

Recombinant immunotoxins directed against the c-erb-2/HER2/neu oncogene product: in vitro cytotoxicity, pharmacokinetics, and in vivo efficacy studies in xenograft models.

M. Rosenblum, J. W. Marks, L. Cheung, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

The development of a functionally relevant cell culture model of progressive human breast cancer.

M J Bissell, V. Weaver, M. Bissell, 1995, Seminars in cancer biology.

Negative Cooperativity between α3β1and α2β1Integrins in Human Mammary Carcinoma MDA MB 231 Cells

Martin R. Schneider, A. Howlett, R. Lichtner, 1998 .

177 Lu-Labeled Phosphoramidate-Based PSMA Inhibitors : The Effect of an Albumin Binder on Biodistribution and Therapeutic Efficacy in Prostate Tumor-Bearing Mice

C. Anderson, C. Berkman, Joseph D Latoche, 2017 .

Negative cooperativity between alpha 3 beta 1 and alpha 2 beta 1 integrins in human mammary carcinoma MDA MB 231 cells.

A. Howlett, R. Lichtner, M. Schneider, 1998, Experimental Cell Research.

Regulation of cellular response to cisplatin-induced DNA damage and DNA repair in cells overexpressing p185erbB-2 is dependent on the ras signaling pathway

S. Richard, M. Alaoui-Jamali, L. Yen, 1997, Oncogene.

First-in-human phase 1 PET study of CTT1057, a novel 18F-labeled imaging agent targeting prostate specific membrane antigen (PSMA) in prostate cancer.

S. Behr, Youngho Seo, H. VanBrocklin, 2017 .